The founding father of EDX Medical has change into the lead investor because it raised £3m to speed up its work on diagnostic check.
Professor Sir Chris Evans, who based the Aquis-listed Medtech in 2021, has invested £740k into the spherical to accumulate 5.3m shares, bringing the 67-year-old’s whole stake within the firm to 36.6%.
Evans was joined by CEO Dr Mike Hudson, and Martin Walton, board director and Deputy Chair, who every subscribed for 60,714 shares.
Evans mentioned: “We’re delighted that new and present buyers within the firm have demonstrated their dedication and perception in our plans to make out there probably the most superior prostate most cancers check and different prime quality diagnostic merchandise.
“This help will allow us to speed up and scale up our growth and manufacturing of our prostate check and different thrilling merchandise in our pipeline.
“We’ve got been thrilled by the extent of curiosity from a number of new buyers in addition to the persevering with help from present buyers and I’m delighted that we achieved our aim of elevating £3 million so quickly.”
Cambridge-based EDX lately developed a brand new ‘tremendous check’ for prostate most cancers during which blood and urine samples are analysed utilizing a mixture of prostate-related biomarkers.
The biomarkers detect, characterise and spotlight indicators of most cancers when processed by means of a specially-created AI-driven algorithm.
Evans is among the most prolific biotech entrepreneurs within the UK, together with greater than 50 corporations of which greater than 20 have been listed on the inventory market. He was awarded the OBE in 1995 earlier than being knighted in 2001 and is believed to have a internet value of upwards of £200m.
Bookmark your favourite posts, get each day updates, and luxuriate in an ad-reduced expertise.
